Kymera Therapeutics (NASDAQ:KYMR) Insider Noah Goodman Sells 2,500 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Noah Goodman sold 2,500 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $99.00, for a total transaction of $247,500.00. Following the sale, the insider directly owned 50,195 shares of the company’s stock, valued at approximately $4,969,305. The trade was a 4.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Noah Goodman also recently made the following trade(s):

• On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.00, for a total transaction of $121,230.00.
• On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.35, for a total value of $174,700.00.
• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.50, for a total value of $723,100.00.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $99.45 on Tuesday. The firm has a market capitalization of $8.18 billion, a P/E ratio of -27.86 and a beta of 2.02. Kymera Therapeutics, Inc. has a 52 week low of $36.65 and a 52 week high of $105.00. The stock has a 50 day moving average price of $83.41 and a two-hundred day moving average price of $81.31.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. The company had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.82) earnings per share. On average, equities analysts forecast that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC lifted its holdings in Kymera Therapeutics by 169.1% during the fourth quarter. SG Americas Securities LLC now owns 22,693 shares of the company’s stock valued at $1,766,000 after purchasing an additional 14,261 shares during the last quarter. Hudson Bay Capital Management LP boosted its holdings in Kymera Therapeutics by 362.7% in the 3rd quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company’s stock valued at $1,309,000 after purchasing an additional 18,134 shares during the period. Eagle Health Investments LP bought a new stake in Kymera Therapeutics during the fourth quarter valued at $10,606,000. Vanguard Group Inc. grew its holdings in shares of Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after purchasing an additional 845,922 shares in the last quarter. Finally, Holocene Advisors LP purchased a new position in Kymera Therapeutics in the 3rd quarter worth approximately $47,563,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Stephens lifted their price objective on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. BTIG Research dropped their price target on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Citigroup boosted their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. UBS Group upped their price objective on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $117.14.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera previously reported quarterly results that beat expectations, with EPS of ($0.71) versus consensus of ($0.89) and revenue of $34.37 million versus estimates of $8.27 million, which supports the bullish long-term thesis.
• Neutral Sentiment: The insider sales were made under pre-arranged Rule 10b5-1 trading plans, which can reduce concern that the transactions reflect a sudden change in outlook.
• Negative Sentiment: Director Bruce Booth sold multiple large blocks of KYMR shares in recent days, including a $24.3 million sale and a $10.5 million sale, which can pressure investor sentiment because of the size and frequency of the transactions. Article Title

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.